Phase III COMBI-i trial of spartalizumab in advanced melanoma fails to meet primary endpoint

Novartis announced that spartalizumab in combination with dabrafenib and trametinib failed to improve progression-free survival in patients with advanced BRAF V600-mutated melanoma vs dabrafenib and trametinib alone. Full data will be presented at a future medical meeting.